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Poster Session II 131recipient respectively. Cumulative incidence of grade II-IV
aGVHD in IG and CG was 25% and 35% respectively (p .
0.05). No difference was seen in days to onset of aGVHD between
the two groups. Patient age, sex, donor type and conditioning reg-
imen had no effect on the probability of response to infliximab.
Rates of chronic GVHD in IG and CG were 84% and 61% respec-
tively (p5 0.22). Pts in IG had significantly more fungal infections
(n5 5) compared to CG (n5 1) (p5 0.02). Kaplan-Meier estimates
of 3 yr overall survival for IG and CG were 31% and 38% respec-
tively (p 5 0.42). Estimates of 3 yr progression free survival are
59% and 56% in similar order (p 5 0.68). Conclusion: In conclu-
sion, infliximab does not reduce incidence of grade II-IV aGVHD
compared to historic controls. It causes a significant increase in fun-
gal infections and may increase the likelihood of chronic GVHD.357
GRAFT-VERSUS-HOST DISEASE: A MINOR-MISMATCHEDMOUSE MODEL
WITH GRADUAL PROGRESSION FROM THE ACUTE INTO THE CHRONIC
PHASE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Shizuru, J.A.1. 1Stanford
School of Medicine, Stanford, CA; 2University Medical Center, Freiburg
i.Br., Germany.
Chronic graft-versus-host disease (cGVHD) is the most frequent
long-term complication after allogeneic hematopoietic cell trans-
plantation (HCT). While acute GVHD (aGVHD) is largely donor
T cell (TC) induced, the pathophysiology of cGVHD remains un-
clear. Amongst the issues to be clarified are the identification of the
TC subsets that drive the pathophysiology, the delineation of anti-
gen targets and the role of B cells (BC). Most experimental models
study acute GVHD, whereas models for the chronic phase are
scarce. C57BL/6 (B6)/BALB. B (H2Db) is an established mi-
nor-mismatched mouse model for aGVHD. Here, we assessed
whether mice also develop chronic long-term symptoms. Lethally
irradiated recipients were given FACS purified hematopoietic
stem cells (HSC: cKit1Thy1.1loLin-Sca11). For induction of
GVHD titrated doses of splenocytes (SP; 5  105–1  107) or pu-
rified CD4 or CD8 TC were co-transferred. Mice were followed
over an extended time (1 y) for clinical signs, weight loss, histology,
chimerism, and IgG synthesis (donor/host). Recipients of pure
HSC remained healthy, steadily increasing in weight (107% of
baseline (BL); d100). Mice given SP developed aGVHD with mor-
bidity and mortality correlating to the SP dose. Survivors of the
acute phase stabilized by d50–70, with only subtle signs for months,
andweight remained belowBL (d100: 93%/83% for 106/107 SP, re-
spectively). Ultimately, they developed a full-blown picture of
cGVHD, with erythrosquamous skin lesions, alopecia, cirrhotic
liver changes, and conjunctivitis at 1 y post-HCT. The most re-
markable histological changes were inflammatory periportal liver
infiltrates, which gradually progressed to fibrosis and complete dis-
ruption of a regular cell pattern. Intestines were primarily affected
in the acute phase, whereas skin changes (subcutaneous atrophy, in-
filtration of hair follicles) manifested late. CD4, but not CD8 TC
induced the full picture of aGVHD. Recipients of HSC remained
mixed chimeras, addition of SP promptly converted recipients to
full donor chimeras. Delays in BC reconstitution correlated with
the degree of aGVHD. Despite this, high levels of donor IgG syn-
thesis were observed. In conclusion, B6/ BALB. B is a valuable
model to study cGVHDwith convincing histological signs evolving
from acute changes. Mouse studies delineating the GVHD-induc-
ing TC subsets will improve our understanding of the pathophysi-
ology of GVHD, and will be an essential piece paving the way of
graft engineering.358
THE PTPN22 1858C/T POLYMORPHISM IS ASSOCIATED WITH THE DE-
VELOPMENT OF GRADE 3 TO 4 ACUTE GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOL-
LOWING NONMYELOABLATIVE CONDITIONING
Kornblit, B.1,2, Masmas, T.1, Petersen, S.L.1, Madsen, H.O.2,
Garred, P.2, Vindelov, L.1. 1Rigshospitalet, University of Copenhagen,Copenhagen, Denmark; 2Rigshospitalet, University of Copenhagen, Co-
penhagen, Denmark.
Graft-versus-host disease (GVHD) is a cause of considerable
morbidity and mortality after allogeneic hematopoietic cell trans-
plantation (HCT) following nonmyeloablative conditioning. Ge-
netic polymorphisms in various genes, associated with the
immune system have been implicated in the development of
GVHD. The PTPN22 gene encodes LYP, which is involved in sup-
pression of T-cell receptor signalling. The 1858 C/T polymor-
phism in PTPN22, renders T-cells hyperresponsive, and the 1858
T allele has been implicated in conferring increased susceptibility
to various autoimmune diseases. As in autoimmunity, T-cell activa-
tion plays a key role in the development of GVHD. To asses the in-
fluence of the PTPN22 1858 C/T polymorphism on development
of GVHD after allogeneic HCT following nonmyeloablative con-
ditioning, 100 consecutive patient-donor pairs receiving allogeneic
HCT with related (n5 66) or unrelated (n5 34) donors for hema-
tological malignancies (HD 5 13, MM 5 14, CLL 5 12, NHL 5
17, MDS 5 18, AML 5 24, CML 5 2), between March 2000 and
December 2005 at Rigshospitalet, Denmark, were genotyped.
The cumulative incidence of grade 2–4 acute GVHD, grade 3–4
acute GVHD and extensive chronic GVHD was 67%, 24%, and
49%, with no difference between patients carrying the C/C or C/
T and T/T genotype or donors carrying the C/C or C/T and T/
T genotype. To assess a possible gene-dosage effect, the number
of T-alleles in each recipient-donor pair was cumulated, and the cu-
mulative incidence of grade 3–4 acute GVHD increased from 20%
in recipient-donor pairs carrying no or oneT-allele to 50% in recip-
ient-donor pairs carrying two or more T alleles (p 5 0.04), while
there was no difference in grade 2–4 acute and extensive chronic
GVHD between groups. In the competing risk regression analysis,
the recipient-donor pair genotype with 2 or more T-alleles was an
independent risk factor (hazard ratio 3.0; 95%CI 1.2–7.5) for devel-
opment of grade 3–4 acute GVHD, even after adjusting for baseline
variables known to affect GVHD rates. Furthermore, patients from
recipient-donor pairs carrying two or more T-alleles were hospital-
ized for more days (p 5 0.01) due to GVHD (median 5 15 days;
range 0–63 d), than patients from recipient-donor pairs with no
or one T-allele (median 5 0 days; range 0–104 d). Collectively,
our data suggest, that the PTPN22 1858 C/T polymorphism,
when present in both recipient and donor, is a risk factor for devel-
opment of grade 3–4 acute GVHD after nonmyeloablative condi-
tioning allogeneic HCT.359
IMMUNE ACTIVATION WITH INTERLEUKIN-2 AND GRANULOCYTE-
MACROPHAGE COLONY STIMULATING FACTOR FOR TREATMENT OF RE-
LAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Bachier, C.R., Shaughnessy, P., Smith, B., Salinas, R., LeMaistre, C.F.
Texas Transplant Institute, San Antonio, TX.
Donor lymphocyte infusion (DLI) is use for relapse after alloge-
neic stem cell transplant (ASCT). Immune activation with cytokines
maybe an alternative to DLI. We studied the use of Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF) and Interleu-
kin-2 (IL-2) for immune activation at the time of relapse after
ASCT in patients (pts) with hematologicmalignancies. Pts. received
subcutaneous GM-CSF at 500 mcg/day on days 1–14 and IL-2 at 1
 106 units/m2/day on days 8–14. Pts. were off immunosuppressive
therapy and had no prior history of graft versus host disease
(GVHD) at the start of treatment. Twelve pts. received IL-2/
GM-CSF for treatment of relapse AML (7), ALL (2), CML (1),
MDS (2). Median age was 55 (range 8–66). Stem cell sources in-
cluded: peripheral blood 5 9, bone marrow 5 2, umbilical cord
blood (UCB) 5 1. Donor sources were: match-related sibling 5 4
and match-unrelated donor5 8 (UCB5 1). Nine pts. had resistant
relapse or primary resistant disease at time of ASCT. Median time
from transplant to relapse was 4 months (range 5 1–14). Two pts.
had failed DLI and 5 pts. had received reinduction chemotherapy
prior to IL-2/GM-CSF. Eight pts. responded to IL-2/GM-CSF
(CR5 7, PR5 1). Two pts. remain disease free at 18 and 26months
post IL-2/GM-CSF. Six pts. developed GVHD and of these 4
were responders. Two pts. had GM-CSF discontinued due to in-
crease in peripheral blood blasts. No other toxicities related to
132 Poster Session IIIL-2/GM-CSF except for mild flu-like symptoms. The table below
summarizes quantitative analysis of immune activation. Values rep-
resent means1/- standard error at day 0 (first day of GM-CSF), day
8 (prior to start of IL-2) and day 14 (last day of IL-2 and GM-CSF).
P-values are based on paired t-test analysis of day 8 versus day 0 and
day 14 versus day 0, respectively. Flow cytometric analysis showed
an increase in the numbers of T-lymphocytes (CD3) andT-cell sub-
sets (CD3/CD8 and CD3/CD4) as well as an increase in natural
killer cells (CD16/56). Although no differences were seen in the
number of dendritic cell subsets, DC1/DC2 ratios decreased with
the administration of GM-CSF/IL-2. Limited (n 5 4) CD4/
FoxP3 analysis did not show change in absolute numbers with
administration of GM-CSF/IL-2 (data not shown). In conclusion,
cytokine therapy with IL-2/GM-CSF is well tolerated and is an
alternative to DLI for relapse after ASCT. Flow cytometry analysis
demonstrated a quantitative increase in immune effector cells and
polarization to DC2.Flow Cytometry of Immune Effector Cells
D0 D8 D14 P-Value P-Value(Mean ± SE) (Mean ± SE) (Mean ± SE) (Day 8–0) (Day 14–0)CD3 (K/uL) 309 ± 117 535 ± 103 1306 ± 403 0.034 0.027CD3/CD8 (K/uL) 94 ± 42 174 ± 33 325 ± 90 0.021 0.029CD3/CD4 (K/uL) 309 ± 117 404 ± 102 977 ± 310 0.249 0.045CD16/CD56 (K/uL) 124 ± 60 404 ± 110 496 ± 162 0.029 0.044CD19 (K/uL) 68 ± 39 89 ± 36 116 ± 31 0.183 0.044Tot. Lymphs (K/uL) 488 ± 167 942 ± 160 2353 ± 532 0.016 0.013CD11(DC1) (K/uL) 97 ± 60 46 ± 32 33 ± 27 0.108 0.101CD123(DC2) (K/uL) 32 ± 7 40 ± 16 45 ± 36 0.694 0.628DC1/DC2 2.77 ± 1.26 0.68 ± 0.35 0.61 ± 0.07SE 5 Standard Error; DC5 dendritic cells.360
WHERE TO BIOPSY IN THE GASTROINTESTINAL (GI) TRACT TO DIAG-
NOSE ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PEDIATRIC
ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (AlloSCT)
Martinez, M., Billote, G., Desai, M., Chu, K., Remotti, H., Satwani, P.,
Cairo, M.S., DeFelice, A. Columbia University, New York, NY.
Background & Aims: Despite therapeutic advances, GI
AGVHD continues to be a serious threat after alloSCT contribut-
ing to significant morbidity and mortality (Yacoub-Agha, et al,
Transplantation 2004). GI endoscopy, although critical to estab-
lishing early diagnosis and grading of AGVHD, poses additional
risks such as bleeding and perforation to already immunocompro-
mised patients. The objective of this study was to determine if upper
GI endoscopy (ED) with duodenum biopsy (Bx) adds diagnostic ac-
curacy to lowerGI ED and colon biopsy in pediatric alloSCT recip-
ients. Methods: We performed a retrospective review of pediatric
alloSCT recipients who underwent upper (UE) and lower (LE)
GI ED at Morgan Stanley Children’s Hospital-New York Presby-
terian between 2001 and 2005. Biopsies were evaluated by a gastro-
intestinal pathologist blinded to clinical data to correlate biopsy
sites with histological findings of GI AGVHD. To examine which
sites were more likely to be diagnostic of AGVHD, six pairwise
comparisons were made between different sites, using the McNe-
mar Test with Bonferroni correction so that p\ 0.008 (50.05/6)
represents statistical significance. Results: We evaluated 50 pa-
tients (age range 0.8 to 17.6 yr, mean 7.6 yr; M 27, F 23) 24 to
100 days post alloSCT suspected of AGVHD who underwent
both upper and lower GI ED. The number of Bx sites per patient
ranged from 4 to 10, median 7. For upper endoscopy, 48 patients
had both duodenal and stomach biopsies, the duodenum was
more likely to be positive than stomach, OR 3.7 (p 5 0.005). For
lower endoscopy cases, there were no significant differences in pro-
portion of positive biopsies between ascending and sigmoid, sig-
moid and transverse, or left versus right colon. However,
comparing LE to UE, left colon was significantly more likely to
be positive than duodenum, OR 12.0 (p 5 0.006). There were 12
cases where the left colon was positive and duodenum negative
and only 1 case where the reverse was true. Conclusions: Overall,duodenum and colon are most likely sites to be positive for GI
AGVHD. Left-sided colonoscopy and left colon biopsy are more
sensitive to detect AGVHD compared to upper endoscopy and gas-
tric and duodenal biopsies. Eliminating concomitant upper endos-
copy and biopsies if a lower endoscopy is performed could
potentially reduce morbidity in pediatric allograft recipients. How-
ever, if upper endoscopy is indicated, duodenal biopsies yield amore
accurate diagnosis than gastric biopsies.361
THE PHARMACODYNAMIC ANALYSIS BETWEEN CYCLOSPORINE A (CsA)
AND CYTOKINE PROFILES OF CD41 T LYMPHOCYTES FOR THE DEVEL-
OPMENT OF OPTIMIZED IMMUNOSUPPRESSIVE THERAPY WITH CsA
AFTER UNRELATED CORD BLOOD TRANSPLANTATION (CBT)
Tsukada, N.1, Ishige, M.2, Konuma, T.1, Kato, S.1, Kasahara, S.1,
Tomonari, A.1, Ooi, J.1, Tojo, A.1, Watanabe, N.2, Nakauchi, H.2,
Masuko, M.3, Furukawa, T.3, Aizawa, Y.3, Takahashi, S.1. 1 Institute
of Medical Science, University of Tokyo, Minato Ward, Tokyo, Japan;
2 Institute of Medical Science, University of Tokyo, Minato Ward, Tokyo,
Japan; 3Niigata University Medical and Dental Hospital, Niigata City,
Niigata, Japan.
Although unrelated cord blood transplantation (CBT) is increas-
ing in number, the optimized immunosuppressive therapy for pre-
vention of graft versus host disease (GVHD) has not been
established. Cyclosporine A (CsA) is the most common immuno-
suppressant used for GVHD prophylaxis and individualization
among types of stem cell source by using therapeutic drug monitor-
ing (TDM) is essential to optimize pharmacotherapy. Cord blood
lymphocytes are naı¨ve and most of CBT are carried out with a hu-
man leukocyte antigen (HLA)-mismatched combination especially
in adults. Our retrospective analysis showedCsA can be tapered ear-
lier for recipients of CBT than for those of BMT. To optimize CsA
administration in CBT, we analyzed proportion of IL-2 producing
cells among CD41T lymphocytes using multi-color flow cytomet-
ric analysis before and after CsA administration. We analyzed 55
peripheral blood samples from 6 allogeneic BMT recipients as con-
trols and 104 peripheral blood samples from 7 CBT recipients.
Cells were cultured in the presence of phorbol 12-myristate 13-ac-
etate, ionomycin, and monensin at 37C for 4 hrs and then stained
for surface markers and intracytoplasmic IL-2. Blood CsA levels
were simultaneouslymeasured.We found that the level of IL-2 pro-
duction in CD41 T lymphocytes was inversely proportional to
blood CsA levels for both BMT and CBT. IL-2 production in
CD41 T lymphocytes of cord blood recipients can be inhibited
by relatively lower CsA concentration compared with that of bone
marrow recipients. To our most interest, there was dramatic differ-
ence in required blood CsA level for inhibition of IL-2 production
by days after transplantation (e.g. before and after day45) in recipi-
ents of CBT, while there was no difference by days after transplan-
tation in recipients of BMT. This finding can explain why earlier
tapering of CsA is possible for cord blood recipients. Further anal-
ysis is needed to optimize blood CsA level on different days after
CBT for GVHD prophylaxis.362
INCIDENCE AND RISK FACTORS FOR CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AFTER CORD BLOOD TRANSPLANTATION (CBT)
Saliba, R.M.1, Couriel, D.2, Komanduri, K.1, Patah, P.3, Westin, J.1,
Giralt, S.1, Cooper, L.4, Petropoulos, D.4, Worth, L.4, Safdar, A.5,
Champlin, R.E.1, Shpall, E.J.1, de Lima, M.1. 1UTMDAnderson Can-
cer Center, Houston, TX; 2Tennesse Oncology, Nashville, TN; 3Hospital
Sirio Libanes, Sao Paulo, Brazil; 4UT MD Anderson Cancer Center,
Houston, TX; 5UT MD Anderson Cancer Center, Houston, TX.
Objective:To evaluate the impact of patient and transplant char-
acteristics on the incidence of cGVHD after CBT.Methods: Ret-
rospective study of all CBT performed at our institution between
1996 and 2007, excluding primary graft failure cases. 114 patients
were analyzed. All had high-risk hematologic malignancies; 59%
were in complete remission or chronic phase at transplantation.
Median age was 37 years (range 18–67) in the adult group (n 5
61) and 7 years (range 0.5–17) in the pediatric group (n 5 53).
